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SUMMARY
We describe a case of a newborn who presented with
multiple dark red macules that developed into red-to-
purple papules associated with thrombocytopaenia.
Abdominal ultrasound showed multiple hyperechoic
papules and nodules. Endothelial cells from a skin
biopsy stained positively for endothelial cell glucose
transporter 1, which was consistent with a diagnosis of
multifocal infantile haemangioma. At the age of
2 months, the child developed intestinal bleeding and
anaemia. Upper and lower endoscopies showed no
intestinal haemangiomas. Oral treatment with
propranolol (3 mg/kg/day) resulted in complete involution
of the skin and hepatic haemangiomas over the period
of treatment, which lasted until the child was aged
15 months. This is a rare case of multifocal cutaneous
haemangioma with hepatic and probable intestinal
involvement, successfully treated with propranolol.
BACKGROUND
Infantile haemangioma (IH) is the most common
vascular tumour in infancy, affecting 3–10% of all
newborns.1 2 Risk factors for the development of
IH are sex (female ratio 3:1), race (Caucasian), pre-
maturity, family history of IH and multiparous
mothers.1 3
IH can be classified as localised, segmental or
multifocal, the latter subtype occurring rarely, in
about 3.6% of all IH.1 Infants with multifocal IH
are recognised to have a higher risk of extracuta-
neous disease, with the liver being the most
affected organ (about 50% of cases), and there are
rare cases of intestinal involvement. We describe a
case of multifocal IH with hepatic and intestinal
involvement that required skin biopsy for differen-
tial diagnosis with other vascular tumours, allowing
appropriate treatment and successful outcome.
CASE PRESENTATION
A full-term male Caucasian newborn, with unre-
markable antenatal and family history, born with
Apgar score of 8 (at 1st and 5th minute), presented
20 min after delivery, with respiratory distress and
multiple widely distributed millimetre-sized dark
red telangiectatic macules. He was found to have
moderate thrombocytopaenia and, due to the
initial suspicion of neonatal sepsis, he was admitted
to the neonatal intensive care unit, where he
required 28% oxygen in the first 24 hours. He was
treated with ampicillin and gentamicin. Although
he was clinically stable, it was noted over the fol-
lowing days that the number of cutaneous lesions—
consisting of red-to-purple papules, ranging in size
from a few millimetres to 1.5 cm (figure 1A–C)—
was increasing (about 30–40) and affecting the
whole body surface, including palms, soles and oral
mucosa. Clinically, there was no hepatosplenome-
galy nor were there any neurological deficits.
Antibiotics were stopped on day 5 due to persist-
ently negative inflammatory markers and negative
blood cultures. At this time, the cutaneous lesions
were investigated. At the age of 2 months, the child
developed intermittent, mild gastrointestinal bleed-
ing (haematemesis and haematochezia), which
resolved over a period of 3 weeks.
INVESTIGATIONS
A full blood count showed moderate thrombocyto-
paenia since birth (minimum of 92 000/ml), which
normalised spontaneously 14 days later, with no
other coagulation disorder.
A biopsy performed from one of the vascular
cutaneous lesions showed small isolated dermal
blood vessels with no lobular arrangement, and
with conspicuous endothelial folds and small septa.
Endothelial cells stained for the glucose transporter
1 (GLUT1) isoform and these were surrounded by
α-smooth muscle actin-positive cells shown to be
pericytes of capillary vessels (figure 2A–C). There
was no expression of lymphatic markers (neither
D2–40/podoplanin nor Prox1). These findings
were consistent with the diagnosis of IH.
Abdominal ultrasound revealed ∼20 round,
hyperechoic papules and nodules in both liver
lobes, with a maximum size of 20 mm, compatible
with hepatic haemangiomas.
Hepatic haemangiomas were confirmed on MRI,
with no involvement elsewhere.
Echocardiography and ECG performed before
starting treatment were normal.
At 2 months, the child was found to have nor-
mocytic normochromic anaemia (minimum haemo-
globin 8.1 g/dL), which preceded the visible
gastrointestinal bleeding. Upper and lower endosco-
pies showed no intestinal haemangiomas.
DIFFERENTIAL DIAGNOSIS
In most cases, IH is diagnosed based on a combin-
ation of typical history and clinical examination.
However, in some atypical cases, a biopsy is
required to exclude other soft tissue tumours such
as multifocal lymphangioendotheliomatosis with
thrombocytopaenia (MLT) and kaposiform hae-
mangioendothelioma (KHE) or neoplastic disorders
such as cutaneous localisation of leukaemia (blue-
berry muffin baby).
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MLT is a rare and recently described entity characterised by
numerous variable skin lesions, ranging from telangiectatic
macules or red–purple plaques 1–2 mm in size to large exophy-
tic haemorrhagic nodules, and extracutaneous disease.
Gastrointestinal involvement is common, with profuse bleeding
and profound thrombocytopaenia. MLT biopsy specimens are
lymphatic vessel endothelial receptor 1-positive and
GLUT1-negative, and do not respond to propranolol treat-
ment.4 Although our case shared some manifestations with
MLT, thrombocytopaenia was moderate and there was only mild
gastrointestinal bleeding.
KHE is a rare GLUT1-negative vasoproliferative tumour with
infiltrative nodules of vascular and lymphatic vessels that pre-
sents at or shortly after birth. Tumours can affect both superfi-
cial and deep soft tissue, arising most often in the limbs, head
and neck. Cutaneous lesions appear raised and blue–red, and
can be complicated by Kasabach-Merritt syndrome and coagula-
tion disorders, a phenomenon not usually seen in IH.5
TREATMENT
At the age of 3 weeks, the patient was started on oral propran-
olol, which was titrated up to 3 mg/kg/day. No adverse effects
on blood glucose, blood pressure or heart rate were noted
during therapeutic monitoring. Abdominal ultrasound was
repeated every 3 months.
Anaemia was treated with iron supplementation (4 mg/kg/day)
for 3 months and no red blood cell transfusion was required.
OUTCOME AND FOLLOW-UP
The patient was followed in a paediatric and gastroenterology
clinic. He maintained normal weight and height growth, with
no haemodynamic impairment and no other complication.
Within the first days of propranolol treatment, the cutaneous
lesions became paler and then progressively involuted
(figure 1D, E), until their complete resolution by the age of
12 months. Ultrasonography confirmed complete resolution of
the hepatic haemangiomas by the age of 15 months, when the
treatment was stopped.
DISCUSSION
Historically, multifocal vascular lesions of infancy have been
categorised as ‘diffuse neonatal haemangiomatosis’ (DNH) or
‘benign neonatal haemangiomatosis’. However, recent develop-
ments in the study of vascular anomalies have highlighted the
confusion in classifying these lesions, which often included
MLT and other less well-characterised multifocal conditions,
with varying prognosis and treatment. Glick et al4 recom-
mended abandoning the term DNH and proposed multifocal
IH with or without extracutaneous disease, a terminology that
we adopted.
In this case, the initial presentation of multifocal cutaneous
lesions and thrombocytopaenia (not commonly found in IH)
triggered investigations into extracutaneous disease and enabled
a precise histopathological diagnosis. IH can be distinguished
from other vascular tumours and malformations by the presence
of immunohistochemical staining for GLUT1,6 7 which was
positive and determined the exact diagnosis.
Platelet count spontaneously normalised prior to starting pro-
pranolol treatment, suggesting an unrelated cause such as neo-
natal hypoxia.
Infants with multifocal IH have a higher risk of hepatic hae-
mangiomatosis, which can lead to heart failure or obstructive
jaundice.8 However, most patients have an excellent prognosis
and low mortality when treatment is started early, as seen in this
case.4
Although gastrointestinal haemangiomas were suspected,
upper and lower gastrointestinal endoscopy were both negative,
a feature also observed in recent series, which cannot exclude
intestinal involvement.9 This is a rare complication of multifocal
IH and seems to be more commonly related to segmental IH
and other vascular anomalies. Moreover, the most frequent loca-
tions of gastrointestinal IH are the small bowel and mesentery,10
which could also explain its absence on endoscopy. MR
Figure 1 Multiple well-defined red-to-purple papules, of various sizes, affecting the whole body surface (A–C), with clear involution after 3 (D)
and 6 (E) months of oral propranolol treatment.
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angiography appears to be a useful non-invasive study,9 but the
resolution of the bleeding in this case justified no further
investigation.
Propranolol is widely considered to be the first-line therapy
for IH, and recent evidence suggests that a dose of 3 mg/kg per
day for 6 months is the most effective.11 IH progresses mainly
during the first 3 months of life, the period during which pro-
pranolol appears to have its maximal therapeutic benefit.
However, some cases of IH may continue to evolve until the
6th–8th month (superficial forms), and until the 9th–12th
month for cases of IH with subcutaneous manifestations.12 In
these cases, more prolonged therapy may be beneficial. In the
absence of evidence regarding the appropriate duration of treat-
ment and due to the extensive involvement, treatment in our
case was continued until the child was aged 15 months, when
complete resolution of hepatic haemangiomas was observed.
Early treatment enabled successful prevention of life-threatening
sequelae.
Our case required coordinated multidisciplinary intervention
and this was crucial to achieve a successful outcome. Infants
with vascular anomalies should be followed in tertiary specialist
paediatric centres in order to have optimal care.
Learning points
▸ Children with more than five cutaneous haemangiomas
should be investigated for extracutaneous disease.
▸ Infants with typical infantile haemangioma (IH) do not
require a skin biopsy for diagnosis.
▸ Cases with extensive lesions present at birth, unusual
cutaneous lesions or extracutaneous involvement, require a
histological diagnosis.
▸ Propranolol is the first-line therapy for glucose transporter
1-positive multifocal IH.
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Figure 2 Infantile haemangioma. (A) Dermal capillary vessels (H&E,
×10); (B) endothelial cell glucose transporter 1 (GLUT1)-positive
endothelial cells and (C) α-smooth muscle actin (ASMA) expressed by
pericytes.
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